ArticleJournal of clinical microbiology2005
Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.Journal of clinical microbiology · 2006Trial
- A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids.Applied microbiology and biotechnology · 2015Article
- Article
- Use of duplex mutation primers for real-time PCR quantification of hepatitis C virus RNA in serum.Hepatitis monthly · 2011Article
- Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits.Journal of clinical microbiology · 2011Article
- Comparisons of three automated systems for genomic DNA extraction in a clinical diagnostic laboratory.Yonsei medical journal · 2010Article
- Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay.Journal of clinical microbiology · 2009Article
- Detection and quantification of hepatitis C virus (HCV) by MultiCode-RTx real-time PCR targeting the HCV 3' untranslated region.Journal of clinical microbiology · 2009Article
- Anomalous quantitation standard growth curves in a laboratory-developed hepatitis C virus (HCV) RNA quantification assay using the TaqMan HCV analyte-specific reagent.Journal of clinical microbiology · 2009Article
- A novel diagnostic target in the hepatitis C virus genome.PLoS medicine · 2009Article
- RNase-resistant virus-like particles containing long chimeric RNA sequences produced by two-plasmid coexpression system.Journal of clinical microbiology · 2008Article
- Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.The Journal of molecular diagnostics : JMD · 2008Article
- Multicenter trials need to use the same assay for hepatitis C virus viral load determination.Journal of clinical microbiology · 2007Article
- Comparison of the abbott 7000 and bayer 340 systems for measurement of hepatitis C virus load.Journal of clinical microbiology · 2007Article
- Preparation of His-tagged armored RNA phage particles as a control for real-time reverse transcription-PCR detection of severe acute respiratory syndrome coronavirus.Journal of clinical microbiology · 2006Article
- Multilaboratory comparison of hepatitis C virus viral load assays.Journal of clinical microbiology · 2006Article
- Broad differences between the COBAS ampliprep total nucleic acid isolation-COBAS TaqMan 48 hepatitis C virus (HCV) and COBAS HCV monitor v2.0 assays for quantification of serum HCV RNA of non-1 genotypes.Journal of clinical microbiology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Performance characteristics of the COBAS hepatitis C virus (HCV) TaqMan analyte-specific reagent (TM-ASR) assay using the QIAGEN BioRobot 9604 for RNA extraction were evaluated and compared to the COBAS Amplicor HCV Monitor V2.0 (Amplicor) and Versant HCV bDNA 3.0 (Versant) assays using clinical samples. Calibration of TM-ASR using Armored RNA allowed determination of the distribution of HCV RNA in clinical samples, using 22,399 clinical samples. Limit of detection, linearity, and inter- and intraassay assay precision were determined for the TM-ASR assay using multiple clinical specimen panels across multiple determinations. Genotype specificity for the TM-ASR assay was determined using samples with different HCV RNA genotypes evaluated and compared against predetermined results. Contamination control of the TM-ASR assay was evaluated using pools of HCV RNA-positive and -negative samples tested in a checkerboard pattern over 12 runs of 96 samples. Correlation of the TM-ASR, Amplicor, and Versant assays was determined using 100 paired clinical samples and Deming regression analysis. The TM-ASR performed well with respect to linearity, precision, and contamination control. The correlation between TM-ASR and the Amplicor and Versant assays was poor, with large differences between assay results for individual samples. Calibration of the TM-ASR assay with Armored RNA allowed for a wide dynamic range and description of the distribution of HCV RNA in clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.